CreativeOne Wealth LLC Purchases 1,302 Shares of Becton, Dickinson and Company (NYSE:BDX)

CreativeOne Wealth LLC grew its position in Becton, Dickinson and Company (NYSE:BDX) by 147.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,185 shares of the medical instruments supplier’s stock after purchasing an additional 1,302 shares during the period. CreativeOne Wealth LLC’s holdings in Becton, Dickinson and Company were worth $527,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its stake in Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after purchasing an additional 1,317,723 shares in the last quarter. Cetera Investment Advisers grew its holdings in shares of Becton, Dickinson and Company by 380.8% during the first quarter. Cetera Investment Advisers now owns 58,923 shares of the medical instruments supplier’s stock worth $14,580,000 after buying an additional 46,668 shares in the last quarter. M&G Plc raised its position in Becton, Dickinson and Company by 0.9% in the 2nd quarter. M&G Plc now owns 709,259 shares of the medical instruments supplier’s stock valued at $165,967,000 after buying an additional 6,052 shares during the last quarter. Benson Investment Management Company Inc. lifted its stake in Becton, Dickinson and Company by 13.2% in the 3rd quarter. Benson Investment Management Company Inc. now owns 22,315 shares of the medical instruments supplier’s stock valued at $5,380,000 after acquiring an additional 2,602 shares in the last quarter. Finally, Swedbank AB grew its stake in shares of Becton, Dickinson and Company by 1.8% during the 3rd quarter. Swedbank AB now owns 150,838 shares of the medical instruments supplier’s stock worth $36,367,000 after acquiring an additional 2,729 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on BDX shares. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Evercore ISI increased their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Stock Performance

BDX opened at $221.90 on Monday. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $249.89. The business’s fifty day moving average is $234.16 and its 200-day moving average is $234.10. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The firm has a market cap of $64.14 billion, a P/E ratio of 37.36, a price-to-earnings-growth ratio of 1.65 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the business posted $3.42 EPS. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.87%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s payout ratio is 63.97%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.